An observational study in Complex Abdominal Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm and Aortic Arch Aneurysm, sponsored by Cook Research Incorporated. Recruiting at 18 sites in 6 countries. Per ClinicalTrials.gov, last updated 2026-06-04.
Sponsored by Cook Research Incorporated (part of Cook Group Incorporated) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Aortic Aneurysm, Thoracoabdominal with a site in Germany — 3 open to participants now, 6 under way, none of them phase 3. Aortic Aneurysm, Thoracoabdominal · Germany.
Among the 10 studies in Aortic Aneurysm, Thoracoabdominal with a site in Germany, this one is the only one that started in 2023, is one of 5 observational ones, and was the 7th registered.
63 studies on the registry are indexed under Aortic Aneurysm, Thoracoabdominal; 31 are open to participants now.
Browse Aortic Aneurysm, Thoracoabdominal studies →3 of the 10 studies in Aortic Aneurysm, Thoracoabdominal with a site in Germany are open now. Recruiting first, the newest first:
Lifetech Scientific (Shenzhen) Co., Ltd. · Sites in Germany
Ages 18–80
Rede Optimus Hospitalar SA · Sites in Germany, Italy, Switzerland
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 25 Aortic Aneurysm, Thoracoabdominal studies recruiting now, 18 (72%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 600 is above the median of 100 across 20 observational studies indexed under Aortic Aneurysm, Thoracoabdominal.
Median enrollment 103 across the 5 interventional studies, 100 across the 5 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 10 have an industry lead sponsor. The 9 most frequent:
This study is registered under Cook Research Incorporated, one of the names counted as Cook Group Incorporated. Under that name alone:
Cook Research Incorporated is the lead sponsor of 33 studies on the registry; 4 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Cook Group Incorporated has 2 studies filed under Aortic Aneurysm, Thoracoabdominal — fewer than ten, so there is no comparison to draw.
1 of the studies in Aortic Aneurysm, Thoracoabdominal with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05896397Cook Research IncorporatedEuropean Aortic Data Collection Project | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Aortic Aneurysm, Thoracoabdominal with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and performance of Cook's various Custom-Made Stent-graft Devices (CMD) used for endovascular treatment of the aorta and related diseases by collecting information on the real-world use of the devices.
The study results will be used to support the continuation of the CMDs on the market. In addition, the study will support the manufacturers obligation for post market product surveillance as well as Cook's technology development.
Patients receiving a Cook custom made endovascular graft within the scope of the study in a maximum of 20 clinical sites in Europe.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. Patients who will be treated with a Cook CMD
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Use of Cook's custom-made endovascular grafts to treat complex abdominal, thoracoabdominal aortic diseases, or aortic arch diseases such as aneurysms and dissections.
Rate of treatment success
Procedural treatment success is defined as successful access to the arterial system using remote arterial exposure, percutaneous technique or open surgical conduits. Success is also defined as successful delivery and deployment of the aortic graft and all stent components, side branch catheterization and placement of bridging stents and patency of all aortic modular stent graft components and intended side branch components.
Time frame: 12 months
Rate of safety outcomes
Safety outcomes is defined as freedom from major adverse events (all-cause mortality, myocardial infarction, disabling stroke, renal failure requiring new-onset dialysis, respiratory failure requiring prolonged (\>24hrs) mechanical ventilation or reintubation, paraplegia, bowel ischemia requiring surgical resection or not resolving with medical therapy)
Time frame: 30 days
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2023 (actual). Primary completion is estimated for Jan 2027, 44 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aortic Aneurysm, Thoracoabdominal →